Dr. John Cush RheumNow
4 years 1 month ago
11.5% of Crohns pts have TNFi use contraindications (either MS, CHF, neoplasia, infx risk, TNFi AE, comorbidities, SLE. Alternatively GI survey respondents use ustekinumab (76%), vedolizumab (249%), or tofacitinib (0.5%) https://t.co/6ApUz93iS0 https://t.co/PTmnsTd2Wh
ARD & RMD Open ARD_BMJ
4 years 1 month ago
Novel autoinflammatory disease with an ALPK1 gain-of-function mutation:
▶️ R etinal dystrophy
▶️ O ptic nerve oedema
▶️ S plenomegaly
▶️ A nhidrosis
▶️ H eadache
https://t.co/9GbjZLMFCo https://t.co/Bh0MkYmrDA
EnvisionRheumat ERheumat
4 years 1 month ago
🌏 Today is World Sjögren's Day!🌍
🩺 Sjögren's is not Just Dry eyes👁️ and Dry Mouth👅👄 - there's much more to it
There's still a lot about this 'invisible' #Autoimmune Disorder, we don't know
Clinical Features and Pathogenesis
#LetstalkaboutSjögrens
#MedTwitter
#RheumTwitter https://t.co/t9toed8MG7
Eric Topol EricTopol
4 years 1 month ago
Anyone who thinks BA.5 is just another variant isn't paying attention
>200,000 new cases yesterday. Vertical. https://t.co/x7wziHMZ9K
Peter Nash drpnash
4 years 1 month ago
Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis https://t.co/6f9yZwUFPb Another IL17 looking promising in GCA!
Dr. John Cush RheumNow
4 years 1 month ago
213 #SLE pts were screened for Cryoglobulinemia (2013 -2017); CG is frequent in SLE (66%), but mostly asymptomatic. Mean levels 40mg/L (0-228). Cryo Vasculitis in 15% w/ purpura, ulcers, digit ischemia, arthritis, GN (5%) or CNS (19%) https://t.co/jRVXCj4MlV https://t.co/gamOOwkJ5R
Dr. John Cush RheumNow
4 years 1 month ago
Overdose deaths increased to 107 000 deaths in US in 2021, with significant racial disparity. Higher overdose rates seen in American Indian, Alaska Natives and Blacks. WORSE during COVID - 2020, overdose rates were 7 times higher in Blacks than Whites https://t.co/PMRo9gbzZl https://t.co/CgxgemyEA7
Dr. John Cush RheumNow
4 years 1 month ago
JAMA patient (resource) handout on Lumbar Spinal Stenosis! https://t.co/fl5K5Ve6fY https://t.co/aLHs6sKE1o
Dr. John Cush RheumNow
4 years 1 month ago
French study from 362 septic arthritis pts over 2 yrs., mean age was 64yrs, w/ high Charlson comorbidity index 3.5. Most common was Knee (39%), Staphylococcus (51%), Abx used 47d, surgery in 48%; 28% serious complications & 9.2% died https://t.co/PdddHsagFg https://t.co/3oHbW0tAjU
Dr. John Cush RheumNow
4 years 1 month ago
Spinal Findings on MRI May Not Signify SpA
Research indicates that rheumatologists should be cautious about diagnosing SpA on the basis of imaging alone.
https://t.co/Z4gox4cx9N https://t.co/PI9BCty8Bx
Dr. John Cush RheumNow
4 years 1 month ago
Leflunomide versus azathioprine in lupus nephritis? Study of 215 bx proven LN given either LEF or AZA - Renal flares were equal (15.7% v 17.8%), as was time to flare (16 mo vs AZA 14 mo); 24-hr proteinuria, creatinine, C3 and C4 improved similarly. https://t.co/2TWmweS2wy https://t.co/0YzlU4vfXP
David Liew drdavidliew
4 years 1 month ago
Sometimes the journey impacts as much as the destination.
TREAT-EARLIER now @TheLancet:
pre-RA (CSA+MRI)
DBRCT: po MTX for 1y (+im mpred120x1) vs placebo
eventual RA same
but persistent benefit at 2y (1y post-MTX cessation):
function, Sx, presenteeism, MRI
a short thread🧵1/7 https://t.co/64b7us6hvS
Dr. John Cush RheumNow
4 years 1 month ago
During 2021-22, there was 387,112 deaths due to pneumonia, influenza, or COVID-19. At least 72% were dut to COVID-19 and 0.6% was due to influenza https://t.co/0ljpXJt0yr https://t.co/1Sp4RULVAY
Dr. John Cush RheumNow
4 years 1 month ago
Sign up for Tuesday Night Rheumatology at 7pm!
https://t.co/MLI4MW7eRW https://t.co/xGln5QN8kp
Are you treating “systemic” or “articular” (arthritis) Still’s disease? Most Still’s patients have a dominance of one or the other. With certainty, the right therapy for the right symptoms can be chosen. What about patients who have an incomplete or no response, or who become unresponsive to a drug that once worked well?
